AU2001252278A1 - Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance - Google Patents

Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance

Info

Publication number
AU2001252278A1
AU2001252278A1 AU2001252278A AU5227801A AU2001252278A1 AU 2001252278 A1 AU2001252278 A1 AU 2001252278A1 AU 2001252278 A AU2001252278 A AU 2001252278A AU 5227801 A AU5227801 A AU 5227801A AU 2001252278 A1 AU2001252278 A1 AU 2001252278A1
Authority
AU
Australia
Prior art keywords
timp
osteo
metalloproteinases
tissue inhibitor
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252278A
Inventor
Wolf-Georg Forssmann
Franz-Josef Kramer
Silke Mark
Ludger Standker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Publication of AU2001252278A1 publication Critical patent/AU2001252278A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to tissue inhibitor of metalloproteinase-2 (TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.
AU2001252278A 2000-04-05 2001-04-04 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance Abandoned AU2001252278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10016791 2000-04-05
DE10016791 2000-04-05
PCT/EP2001/004891 WO2001074380A2 (en) 2000-04-05 2001-04-04 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance

Publications (1)

Publication Number Publication Date
AU2001252278A1 true AU2001252278A1 (en) 2001-10-15

Family

ID=7637590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252278A Abandoned AU2001252278A1 (en) 2000-04-05 2001-04-04 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance

Country Status (9)

Country Link
US (1) US7232796B2 (en)
EP (1) EP1267916B1 (en)
JP (1) JP4939715B2 (en)
AT (1) ATE270110T1 (en)
AU (1) AU2001252278A1 (en)
CA (1) CA2404696C (en)
DE (1) DE50102739D1 (en)
ES (1) ES2219521T3 (en)
WO (1) WO2001074380A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10102784A1 (en) * 2001-01-22 2002-08-01 Henkel Kgaa Cosmetic or pharmaceutical preparations for the treatment of epithelial cover tissue
US8776119B2 (en) * 2007-05-04 2014-07-08 Cox Communications, Inc. Displaying an information ticker in association with a personalized video mosaic in a television services network
EP3046575A4 (en) * 2013-09-18 2017-04-05 James Cook University Anti-inflammatory proteins and methods of use
CN105745223A (en) 2013-09-18 2016-07-06 詹姆斯库克大学 Acylated glucagon analogues
EP3569698A1 (en) * 2018-05-16 2019-11-20 Veterinärmedizinische Universität Wien Products for therapy of a musculoskeletal condition and methods for their production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3156082B2 (en) * 1989-03-21 2001-04-16 アメリカ合衆国 Matrix metalloproteinase inhibitor peptide
AU648505B2 (en) * 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5174465A (en) * 1991-03-05 1992-12-29 Cap Snap Co. One-piece fitment and cap with tamper-evident band
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh Systemic gene treatment of connective tissue diseases
US5643752A (en) * 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
GB9615976D0 (en) * 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
EP1009444A2 (en) * 1997-09-02 2000-06-21 Chiron Corporation Compositions and methods for treating arthritis utilizing gene therapy

Also Published As

Publication number Publication date
WO2001074380A2 (en) 2001-10-11
US20030195143A1 (en) 2003-10-16
EP1267916A2 (en) 2003-01-02
CA2404696A1 (en) 2001-10-11
DE50102739D1 (en) 2004-08-05
EP1267916B1 (en) 2004-06-30
WO2001074380A3 (en) 2002-02-07
CA2404696C (en) 2010-06-15
ES2219521T3 (en) 2004-12-01
JP2003528923A (en) 2003-09-30
JP4939715B2 (en) 2012-05-30
US7232796B2 (en) 2007-06-19
ATE270110T1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
MXPA05006359A (en) Disease treatment via antimicrobial peptide inhibitors.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
HK1068811A1 (en) Substituted oxazolidinones for combinational therapy
TR200101120T2 (en) Serine protease inhibitor
WO2003103662A3 (en) Inhibitors of glycoprotein vi
AU2855399A (en) Vascularization inhibitors
DE60137635D1 (en) USE OF ALLOPURINOL FOR THE TREATMENT OF BLOOD HIGH PRESSURE
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
GB2352972A (en) Use of dexmedetomidine for icu sedation
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2005060960A3 (en) Use of histamine to treat bone disease
AU2001252278A1 (en) Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
GB9930768D0 (en) Composition
WO2001034565A3 (en) Protease inhibitors
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
NZ519722A (en) Treatment of diabetic ulcers
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
ATE341323T1 (en) USE OF DARIFENACIN TO TREAT URINATION
WO2003044058A3 (en) Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
GR1004434B (en) Use of diflofenac or topically acceptable salt thereof for the treatment of burns
AU9627898A (en) Tightening and/or reducing the size of body parts containing fat cells
AU5434899A (en) Cancer treatment